The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Resetting Immune Tolerance for the Prevention of RA

Resetting Immune Tolerance for the Prevention of RA

November 10, 2020 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR Convergence 2020ACR CONVERGENCE 2020—Rheumatoid arthritis (RA) has been postulated to develop in several phases, with inherited susceptibility factors in some cases leading to asymptomatic (or preclinical) citrullinated protein-directed autoimmunity, followed, after some interval, by the development of synovial infiltration and polyarticular disease. We know early treatment of RA is critical to reduce disease symptoms and slow disease progression. So is it possible to identify and treat at-risk patients during the preclinical phase to prevent disease onset?

You Might Also Like
  • Resetting Immune Tolerance to Prevent RA
  • 2015 ACR/ARHP Annual Meeting: Research Provides Insights into Immune Regulation and Tolerance
  • 2015 ACR/ARHP Annual Meeting: RA Pathogenesis and Prevention
Also By This Author
  • Racial Bias Found in Pain Assessment, Management, Treatment Recommendations by Clinicians

This session, moderated by Stanford University’s William Robinson, MD, PhD, and presented by Ronald F. Van Vollenhoven, MD, PhD, Amsterdam UMC; Peter Taylor, MD, PhD, MA, University of Oxford; and V. Michael Holers, MD, University of Colorado, reviewed research underway to examine pathogenic mechanisms responsible for the development of preclinical autoimmunity and subsequent overt disease. A case was made for the role of B cells in disease development and the rationale for targeting these cells in people identified at risk of RA.

V. Michael Holers, MD

Ronald F Van Vollenhoven, MD, PhD

Ronald F Van Vollenhoven, MD, PhD

Other research suggests that preclinical disease may be initiated in mucosal sites, primarily in the lung, due to molecular changes from environmental exposures such as cigarette smoke. Further research may pave the way for therapeutically targeting the mechanisms of preclinical disease.

Watch this site for a full report on this session.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Filed Under: ACR Convergence, Meeting Reports Tagged With: ACR Convergence 2020, ACR Convergence 2020 – RA

You Might Also Like:
  • Resetting Immune Tolerance to Prevent RA
  • 2015 ACR/ARHP Annual Meeting: Research Provides Insights into Immune Regulation and Tolerance
  • 2015 ACR/ARHP Annual Meeting: RA Pathogenesis and Prevention
  • Destructive Arthritis: From Prevention to Progression to Remission

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)